(6-(2-amino-1,3-benzoxazol-5-yl)imidazo(1,2-a)pyridin-3-yl)(4-morpholinyl)methanone,
INK1117,
MLN1117,
serabelisib,
TAK-117,
Serabelisib,
1268454-23-4,
MLN1117,
INK-1117,
INK1117,
UNII-43J9Q56T3W,
TAK-117,
MLN-1117,
43J9Q56T3W,
(6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone,
Serabelisib (INK-1117,MLN-1117,TAK-117),
[6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone,
AGN-PC-0DB6FL,
Methanone, (6-(2-amino-5-benzoxazolyl)imidazo(1,2-a)pyridin-3-yl)-4-morpholinyl-,
Methanone, [6-(2-aMino-5-benzoxazolyl)iMidazo[1,2-a]pyridin-3-yl]-4-Morpholinyl-,
Serabelisib [INN],
GTPL8969,
CHEMBL3935857,
SCHEMBL12928418,
KS-00000TSW,
BDBM119531,
BCP09230,
EX-A1112,
INK 1117,
MLN 1117,
MLN1117; INK1117,
MFCD15146372,
s8581,
AKOS030526373,
MLN1117 (INK1117),
ZINC146965425,
CS-5490,
AK547176,
HY-12285,
TAK-117(INK1117 MLN1117),
MLN1117, INK1117, TAK-117,
A15529,
US9682141, 54,
US9682141, 529,
(6-(2-Amino-5-benzoxazolyl)imidazo(1,2-a)pyridin-3-yl)-4-morpholinylmethanone,
5-[3-(morpholine-4-carbonyl)imidazo[1,2-a]pyridin-6-yl]-1,3-benzoxazol-2-amine,
Methanone,[6-(2-aMino-5-benzoxazolyl)iMidazo[1,2-a]pyridin-3-yl]-4-Morpholinyl-,
1428967-74-1,